Co-Diagnostics Submits Co-Dx PCR Flu A/B & RSV Test for FDA Clearance
Co-Diagnostics submitted a dual 510(k) premarket notification and CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV multiplex respiratory test.
Co-Diagnostics submitted a dual 510(k) premarket notification and CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV multiplex respiratory test.
A recent cruise ship outbreak of the Andes strain underscores the potential for silent spread and severe respiratory complications in travel networks.
Masimo has appointed Tim Benner as president, effective August 3, 2026, according to a company news release.
The COPD Foundation announced an upcoming meeting to ensure patient experiences and priorities are incorporated into the future of therapeutic development.